Table 2.
Clinical and Histopathologic Features with Presence or Absence of Neuroendocrine Cell Micronests.
| Neuroendocrine cell micronests |
P value | ||
|---|---|---|---|
| Present (n = 37) | Absent (n = 23) | ||
|
| |||
| n (%) | n (%) | ||
|
| |||
| Treatment | |||
| Chemoradiationa (n = 54) | 34 (63%) | 20 (37%) | .86 |
| Chemotherapy only (n = 6) | 3 (50%) | 3 (50%) | |
| Interval from last treatment to specimen collection | |||
| < = 30 days (n = 12) | 5 (42%) | 7 (58%) | .33 |
| 3–60 days (n = 35) | 24 (69%) | 11 (31%) | |
| >60 days (n = 12) | 7 (58%) | 5 (42%) | |
| Unknown (n = 1) | 1 (100%) | 0 (0%) | |
| Location | |||
| Gastroesophageal junction/gastric cardia (n = 32) | 26 (81%) | 6 (19%) | .006 |
| Gastric body (n = 2) | 1 (50%) | 1 (50%) | |
| Gastric antrum (n = 24) | 10 (42%) | 14 (58%) | |
| Pylorus (n = 2) | 0 (0%) | 2 (100%) | |
| Therapy-related epithelial changes | |||
| Present (n = 50) | 34 (68%) | 16 (32%) | .06 |
| Absent (n = 10) | 3 (30%) | 7 (70%) | |
Bold values indicate statistical significance, P value < .05
a
Includes 1 patient treated with chemotherapy and yttrium radioembolization.